WeVote
Log In

Bill

Bill

S 1965

Restores medical futility as a basis for DNR

2025 Regular Session Introduced by Gustavo Rivera

NJ bill codifies pharmacy safeguards in long-term care: consultant pharmacists attest no ties to the facility's pharmacy or director, and a P&T committee oversees medications.

REFERRED TO HEALTH
0
WeVote Research Nonpartisan
Bill Summary · S 1965

Summary — S.1965 (1R)

Short title: An Act concerning long‑term care facilities and pharmaceutical services (supplementing Title 26 of the Revised Statutes)

Note on metadata: the materials provided contain mixed or inconsistent metadata (an earlier title referencing DNR/medical futility, a Massachusetts docket, and a federal sponsor list). This summary focuses on the New Jersey bill text and committee statements contained in the documents, which address pharmaceutical services and conflict‑of‑interest safeguards in long‑term care facilities.

Main purpose

To codify existing New Jersey Department of Health regulations on pharmaceutical services in long‑term care facilities and to add a statutory requirement that consultant pharmacists attest they have no affiliation with the facility’s pharmacy provider or director of pharmaceutical services and avoid conflicts of interest.

Key provisions

  • Definitions

    • “Long‑term care facility” — a facility (or distinct part of a facility) licensed by the New Jersey Department of Health as a long‑term care facility (examples in prior language included nursing homes, assisted living, etc.).
    • “Pharmacist” — a person licensed under state pharmacy law.

  • Pharmacist roles and qualifications

    • Each long‑term care facility must have:
    • a consultant pharmacist, and
    • either a provider pharmacist or, if the facility operates an in‑house pharmacy, a director of pharmaceutical services.
    • The director of pharmaceutical services or consultant pharmacist must be a New Jersey‑licensed pharmacist and comply with applicable federal and state laws and accepted professional standards.

  • Conflict‑of‑interest safeguard for consultant pharmacists

    • The facility must appoint a consultant pharmacist who is not also the director of pharmaceutical services or the pharmacist provider.
    • The consultant pharmacist must attest that they do not have an affiliation with the facility’s director of pharmaceutical services or pharmacist provider.
    • After appointment, the consultant pharmacist must avoid all real or potential conflicts of interest with those parties.

  • Pharmacy & Therapeutics (P&T) committee

    • Each facility must maintain an interdisciplinary P&T committee appointed by and reporting to the facility administrator.
    • Committee membership must include at minimum: the administrator, a nursing staff representative, and the facility’s consultant pharmacist. The facility’s medical director may provide oversight as needed; a licensed pharmacist representing the provider pharmacy may be included.
    • The committee must meet at least quarterly and maintain records (meeting dates, attendance, activities, findings, recommendations).

  • Controlled substances

    • If the facility stores emergency injectable or oral controlled substances, a current DEA registration and controlled dangerous substance registration for the location must be available.

  • Implementation

    • The Commissioner of Health is directed to adopt rules and regulations necessary to effectuate the act.
    • The act takes effect immediately upon enactment.

Who is affected

  • Long‑term care facilities licensed by the NJ Department of Health (nursing homes, assisted living/residential health care settings, dementia care units, etc.).
  • Consultant pharmacists, provider pharmacists, and directors of pharmaceutical services.
  • Facility administrators and P&T committee members.
  • Indirectly, facility residents through strengthened oversight of medication management and reduced potential for vendor/provider conflicts.

Potential impacts and considerations

  • Intended outcomes: improved transparency and independence in pharmacy oversight, reduction of real/potential conflicts of interest, strengthened medication safety governance through required P&T committees and records.
  • Administrative effects: facilities may need to ensure separate staffing/contracting arrangements (or hire independent consultant pharmacists) and maintain committee records; DOH rulemaking will further specify requirements.
  • Fiscal impact: not specified in the bill text; potential modest costs for facilities to contract independent consultants or to strengthen compliance/recordkeeping systems.
  • Enforcement and oversight will be implemented through DOH regulations under the Administrative Procedure Act.

Legislative status (selected events from provided record)

  • Introduced in Senate: Jan 9, 2024 (referred to Senate Health, Human Services & Senior Citizens Committee).
  • Reported out of Senate committee with amendments: Mar 14, 2024.
  • Passed Senate: May 20, 2024 (37–0).
  • Referred to Assembly Health Committee upon reception: May 20, 2024.
  • Assembly Health Committee reported favorably: Nov 24, 2025.
  • Additional hearings and referrals noted in the record; final enactment status not shown in the materials provided.

If you want, I can:
- Draft a one‑page explainer for facility administrators on compliance steps, or
- Extract the specific regulatory changes likely to be required for DOH rulemaking.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.